| __timestamp | Ionis Pharmaceuticals, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 4241601.57 |
| Thursday, January 1, 2015 | 37173000 | 5392385.38 |
| Friday, January 1, 2016 | 48616000 | 7370036.73 |
| Sunday, January 1, 2017 | 108488000 | 14970357 |
| Monday, January 1, 2018 | 244622000 | 31413266 |
| Tuesday, January 1, 2019 | 287000000 | 72279461 |
| Wednesday, January 1, 2020 | 354000000 | 183907682 |
| Friday, January 1, 2021 | 186000000 | 307644000 |
| Saturday, January 1, 2022 | 151000000 | 472132000 |
| Sunday, January 1, 2023 | 232600000 | 709539000 |
| Monday, January 1, 2024 | 267474000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Ionis Pharmaceuticals, Inc. and argenx SE have demonstrated contrasting approaches to SG&A expenditures. From 2014 to 2023, Ionis Pharmaceuticals saw a steady increase in SG&A spending, peaking in 2020 with a 1,660% rise from 2014 levels. However, their spending saw a decline post-2020, dropping by 57% by 2022. In contrast, argenx SE's SG&A expenses skyrocketed, especially from 2018 onwards, culminating in a staggering 16,600% increase by 2023 compared to 2014. This divergence highlights argenx SE's aggressive expansion strategy, while Ionis Pharmaceuticals appears to be optimizing its operational costs. As these companies continue to evolve, their SG&A strategies will likely play a pivotal role in shaping their market positions.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc
Comparing SG&A Expenses: argenx SE vs Veracyte, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited